BRPI0311176B8 - pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica - Google Patents

pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica

Info

Publication number
BRPI0311176B8
BRPI0311176B8 BRPI0311176A BR0311176A BRPI0311176B8 BR PI0311176 B8 BRPI0311176 B8 BR PI0311176B8 BR PI0311176 A BRPI0311176 A BR PI0311176A BR 0311176 A BR0311176 A BR 0311176A BR PI0311176 B8 BRPI0311176 B8 BR PI0311176B8
Authority
BR
Brazil
Prior art keywords
pseudopolymorph
ethanolate
pharmaceutical composition
preparation process
pseudopolymorphic forms
Prior art date
Application number
BRPI0311176A
Other languages
English (en)
Other versions
BR0311176A (pt
BRPI0311176B1 (pt
Inventor
Joseph Christiaan Thoné Daniel
Wim Pieter Vermeersch Hans
Donné Marie-Louise Janssens Luc
Tom Bert Paul Wigerinck Piet
Original Assignee
Janssen Sciences Ireland Uc
Janssen R&D Ireland
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0311176(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc, Janssen R&D Ireland, Tibotec Pharm Ltd filed Critical Janssen Sciences Ireland Uc
Publication of BR0311176A publication Critical patent/BR0311176A/pt
Publication of BRPI0311176B1 publication Critical patent/BRPI0311176B1/pt
Publication of BRPI0311176B8 publication Critical patent/BRPI0311176B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

formas pseudopolimórficas de um inibidor da protease do hiv. a presente invenção refere-se a novas formas pseudopolimórficas de (3r,3as,6ar)-hexahidrofuro[2,3-b] furan-3-il (1s,2r)-3-[[(4-aminofenil) sulfonil] (isobutil) amino]-1-benzil-2-hidroxipropilcarbamato e processos para a produção das mesmas.
BRPI0311176A 2002-05-16 2003-05-16 pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica BRPI0311176B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02076929 2002-05-16
EP02076929.5 2002-05-16
PCT/EP2003/050176 WO2003106461A2 (en) 2002-05-16 2003-05-16 Pseudopolymorphic forms of a hiv protease inhibitor

Publications (3)

Publication Number Publication Date
BR0311176A BR0311176A (pt) 2005-03-15
BRPI0311176B1 BRPI0311176B1 (pt) 2019-08-20
BRPI0311176B8 true BRPI0311176B8 (pt) 2021-05-25

Family

ID=29724454

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0311176A BRPI0311176B8 (pt) 2002-05-16 2003-05-16 pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica

Country Status (25)

Country Link
US (8) US7700645B2 (pt)
EP (4) EP1567529B2 (pt)
JP (1) JP4864320B2 (pt)
KR (2) KR20100119906A (pt)
CN (1) CN100475819C (pt)
AP (1) AP2052A (pt)
AU (2) AU2003271740B2 (pt)
BR (1) BRPI0311176B8 (pt)
CA (1) CA2485834C (pt)
CY (3) CY1115665T1 (pt)
DK (3) DK2314591T4 (pt)
EA (1) EA007120B8 (pt)
ES (4) ES2503551T5 (pt)
HR (1) HRP20041061B1 (pt)
HU (1) HUE034389T2 (pt)
IL (1) IL165140A0 (pt)
LT (1) LT2767539T (pt)
MX (1) MXPA04011427A (pt)
NO (1) NO331477B1 (pt)
NZ (1) NZ536497A (pt)
PL (1) PL215151B1 (pt)
PT (3) PT2314591E (pt)
SI (3) SI2767539T1 (pt)
WO (1) WO2003106461A2 (pt)
ZA (1) ZA200410154B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872424C (en) 1998-06-23 2017-03-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Bisfuran derivatives useful in preventing the emergence of multidrug resistant hiv strains and treatment of hiv
BRPI0311176B8 (pt) 2002-05-16 2021-05-25 Janssen Sciences Ireland Uc pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
JP4818124B2 (ja) 2003-12-23 2011-11-16 テイボテク・フアーマシユーチカルズ・リミテツド （３Ｒ，３ａＳ，６ａＲ）−ヘキサヒドロフロ〔２，３−ｂ〕フラン−３−イル（１Ｓ，１Ｒ）−３−〔〔（４−アミノフェニル）スルホニル〕（イソブチル）アミノ〕−１−ベンジル−２−ヒドロキシプロピルカルバマートの製造方法
DK1856125T3 (da) 2005-02-25 2009-12-07 Tibotec Pharm Ltd Syntese af proteasehæmmerforstadie
CN102432621B (zh) * 2006-11-09 2016-02-17 爱尔兰詹森科学公司 六氢呋喃并[2,3-b]呋喃-3-醇的制备方法
TWI482775B (zh) 2008-09-01 2015-05-01 Tibotec Pharm Ltd 用於製備（３ｒ，３ａｓ，６ａｒ）－六氫呋喃并〔２，３－ｂ〕呋喃－３－基（１ｓ，２ｒ）－３－〔〔（４－胺基苯基）磺醯基〕（異丁基）胺基〕－１－苯甲基－２－羥基丙基胺基甲酸酯之方法
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
MX2011007790A (es) 2009-01-29 2011-11-18 Mapi Pharma Ltd Polimorfos de darunavir.
CA2776807C (en) * 2009-09-17 2018-10-16 Mylan Laboratories Limited An improved process for the preparation of darunavir
WO2011051978A2 (en) 2009-10-30 2011-05-05 Lupin Limited A novel process for preparation of darunavir and darunavir ethanolate of fine particle size
CN102686594A (zh) * 2009-12-16 2012-09-19 熙德隆研究基金会 地瑞那韦的多晶型物
NZ600994A (en) * 2010-01-05 2014-04-30 Cipla Ltd Darunavir polymorph and process for preparation thereof
EP2528923B1 (en) 2010-01-28 2014-07-30 Mapi Pharma Limited Process for the preparation of darunavir and darunavir intermediates
WO2011145099A1 (en) * 2010-05-20 2011-11-24 Hetero Research Foundation Crystalline hydrochloride salt of darunavir
WO2012107889A1 (en) 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of amorphous darunavir
EP2729130B1 (en) 2011-07-07 2017-09-06 Janssen Sciences Ireland UC Darunavir combination formulations
WO2013114382A1 (en) 2011-12-05 2013-08-08 Mylan Laboratories Ltd Crystalline darunavir
US9643976B2 (en) * 2012-01-18 2017-05-09 Aurobindo Pharma Ltd. Solvates of darunavir
CN103509031B (zh) * 2012-06-20 2016-04-27 上海迪赛诺药业有限公司 制备达芦那韦无定形物的方法
EP3795572B1 (en) 2012-07-24 2023-11-15 Laurus Labs Limited Darunavir propionate solvate
EP2912047B1 (en) 2012-10-29 2016-08-24 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US9346820B2 (en) * 2013-09-11 2016-05-24 Purdue Research Foundation HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
WO2016092525A1 (en) * 2014-12-12 2016-06-16 Lupin Limited Darunavir n-propanol solvate and process for preparation thereof
KR102603277B1 (ko) * 2015-03-19 2023-11-17 마이코비아 파마슈티컬즈, 인코포레이티드 항진균성 화합물 및 이의 제조 방법
ES2952878T3 (es) 2016-08-08 2023-11-06 Hetero Labs Ltd Una composición antirretroviral multiclase
BR112019002132A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composições anti-retrovirais
ES2881949T3 (es) 2016-10-27 2021-11-30 Gilead Sciences Inc Forma cristalina de base libre de darunavir
CN108727401A (zh) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 达鲁那韦新晶型及其制备方法和应用
CN109053753A (zh) * 2018-08-05 2018-12-21 浙江大学 一种制备达卢那韦二水合物晶型的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
JPH05230044A (ja) 1992-02-21 1993-09-07 Hoechst Japan Ltd ピレタニドの新規な結晶多形
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
EP0715618B1 (en) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
DK0812320T3 (da) * 1995-02-22 2003-04-14 Aventis Pharma Ltd Amorft piretanid, polymorfe former deraf, fremgangsmåde til fremstilling deraf og deres anvendelse
ZA984514B (en) * 1997-05-29 1998-11-30 Merck & Co Inc Hiv protease inhibitor
GB9712253D0 (en) 1997-06-13 1997-08-13 Glaxo Group Ltd Antiviral compound
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9805898D0 (en) * 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
CA2872424C (en) 1998-06-23 2017-03-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Bisfuran derivatives useful in preventing the emergence of multidrug resistant hiv strains and treatment of hiv
AU4828199A (en) * 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
CA2345516A1 (en) 1998-11-19 2000-05-25 Dupont Pharmaceuticals Company Crystalline (-)-6- chloro-4- cyclopropylethynyl- 4-trifluoromethyl- 3,4-dihydro- 2(1h)-quinazolinone
JP4814427B2 (ja) 1999-02-12 2011-11-16 バーテックス ファーマシューティカルズ インコーポレイテッド アスパルチルプロテアーゼのインヒビター
BRPI0311176B8 (pt) 2002-05-16 2021-05-25 Janssen Sciences Ireland Uc pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica
NZ600994A (en) * 2010-01-05 2014-04-30 Cipla Ltd Darunavir polymorph and process for preparation thereof

Also Published As

Publication number Publication date
US20170260196A1 (en) 2017-09-14
AU2003271740B2 (en) 2010-05-13
SI1567529T1 (sl) 2014-11-28
US20210179631A1 (en) 2021-06-17
ZA200410154B (en) 2005-12-28
KR101128370B1 (ko) 2012-04-23
CN100475819C (zh) 2009-04-08
US20140171499A1 (en) 2014-06-19
EP2767539A1 (en) 2014-08-20
PT2314591E (pt) 2014-09-19
EP1567529B1 (en) 2014-06-18
SI2314591T2 (sl) 2021-08-31
EP3045460B1 (en) 2019-04-17
HUE034389T2 (en) 2018-02-28
EP1567529A2 (en) 2005-08-31
NO20045409L (no) 2004-12-10
US10000504B2 (en) 2018-06-19
LT2767539T (lt) 2017-09-25
HRP20041061B1 (hr) 2015-02-27
SI1567529T2 (sl) 2021-08-31
EA200401503A1 (ru) 2005-06-30
EP3045460A1 (en) 2016-07-20
DK1567529T3 (da) 2014-09-15
CY1119311T1 (el) 2018-02-14
WO2003106461A2 (en) 2003-12-24
PL374321A1 (en) 2005-10-17
CA2485834A1 (en) 2003-12-24
EA007120B8 (ru) 2012-03-30
DK2314591T3 (da) 2014-09-22
ES2503551T5 (es) 2021-10-28
US20150336980A1 (en) 2015-11-26
CY1115665T1 (el) 2017-01-25
US8518987B2 (en) 2013-08-27
AP2052A (en) 2009-10-05
KR20050008715A (ko) 2005-01-21
US20180312517A1 (en) 2018-11-01
BR0311176A (pt) 2005-03-15
ES2728735T3 (es) 2019-10-28
IL165140A0 (en) 2005-12-18
EP1567529B2 (en) 2021-02-24
DK2314591T4 (da) 2021-05-10
JP4864320B2 (ja) 2012-02-01
MXPA04011427A (es) 2005-02-17
US10858369B2 (en) 2020-12-08
ES2638412T3 (es) 2017-10-20
DK2767539T3 (en) 2017-09-11
US7700645B2 (en) 2010-04-20
AP2004003191A0 (en) 2004-12-31
US20100204316A1 (en) 2010-08-12
PT2767539T (pt) 2017-08-28
HK1081969A1 (en) 2006-05-26
SI2314591T1 (sl) 2014-11-28
PT1567529E (pt) 2014-09-09
US20130303790A1 (en) 2013-11-14
EP2314591B1 (en) 2014-06-18
NZ536497A (en) 2006-08-31
CY1117928T1 (el) 2017-05-17
AU2012205289A1 (en) 2012-08-09
BRPI0311176B1 (pt) 2019-08-20
US20050250845A1 (en) 2005-11-10
EP2767539B1 (en) 2017-07-12
PL215151B1 (pl) 2013-10-31
WO2003106461A3 (en) 2004-05-13
HRP20041061A2 (en) 2006-07-31
CN1668623A (zh) 2005-09-14
EP2314591A1 (en) 2011-04-27
SI2767539T1 (sl) 2017-10-30
ES2498370T3 (es) 2014-09-24
EP2314591B2 (en) 2021-02-24
EA007120B1 (ru) 2006-06-30
ES2503551T3 (es) 2014-10-07
DK1567529T4 (da) 2021-05-10
KR20100119906A (ko) 2010-11-11
NO331477B1 (no) 2012-01-16
AU2003271740A1 (en) 2003-12-31
JP2005533068A (ja) 2005-11-04
CA2485834C (en) 2007-07-17
ES2498370T5 (es) 2021-11-24

Similar Documents

Publication Publication Date Title
BRPI0311176B8 (pt) pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica
CY1119150T1 (el) ΜΕΘΟΔΟΙ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ (3R,3aS,6aR) ΕΞΑΫΔΡΟ-ΦΟΥΡΟ[2,3-b]ΦΟΥΡΑΝ-3-ΟΛΗΣ
BRPI0417272B8 (pt) processo para a preparação de (3r, 3as, 6ar)-hexahidrofuro [2,3-b] furan-3-il (1s, 2r)-3-[[(4-aminofenil) sulfonil] (isobutil) amino]-1-benzil-2-hidroxipropilcarbamato
AR119702A2 (es) Proceso para la preparación de (1s,2r)-3-[[(4-aminofenil)sulfonil](isobutil)amino]-1-bencil-2-hidroxipropilcarbamato de (3r,3as,6ar)-hexahidrofuro[2,3-b]furan-3-ilo
CY1109974T1 (el) Μεθοδος για την παρασκευη εξαϋδρο-φουρο[2,3-β]φουραν-3-ολης
TWD209419S (zh) 輪胎（２５９）
AR019388A1 (es) (3s) tetrahidro-3-furanil (1s, 2r)-3-[[(4-aminofenil)sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamato de calcio y composiciones del mismo,su uso en el tratamiento de infecciones retrovirales y procesos para su preparacion.
HUP0400333A2 (hu) Kristályos antikolinergikum, eljárás előállítására és alkalmazása gyógyszerkészítmény előállítására
BR122019020833B8 (pt) agente antiviral [1s-(1alfa, 3alfa, 4beta)]-2-amino-1,9-diidro-9-[4-hidróxi-3-(hidroximetil)-2-metilenociclopentil]-6h-purin-6-ona
MA30000B1 (fr) Nouvelle forme cristalline d'un derive de pyridazino [4,5-b] indole
BR112012018862A2 (pt) processo para a preparação de darunavir e intermediários de darunavir
ES2186115T3 (es) Dispositivo de union para pasamanos.
BRPI0405415A (pt) Pneu otr com baixa relação entre lìquido e bruto
UY27413A1 (es) Agonistas de la oxitocina
WO2011051978A3 (en) A novel process for preparation of darunavir and darunavir ethanolate of fine particle size
AR019477A1 (es) Triazolopiridinas para el tratamiento de los trastornos de la trombosis
EP3313847A4 (en) PROCESS FOR THE PREPARATION OF [(S 1,2R) -3 - [[(4-AMINOPHENYL) SULFONYL] (2-METHYLPROPYL) AMINO] -2-HYDROXY-1- (PHENYLMETHYL) PROPYL] -carbamic Acid (3R, 3AS, 6AR ) HEXAHYDRO-FURO [2,3-B] FURAN-3-YL ESTER AND ITS AMORPH FORM
BR0308291A (pt) Derivados de artemisinin (endoperóxidos) antiparasìticos
CL2025000550A1 (es) Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metoxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida.
BR0007854A (pt) Compostos sulfonamidas bis-aminoácidos inibidores de protease de hiv, composição farmacêutica e método de tratamento de infecções por hiv
BR0214068A (pt) Preparação de derivados 3,3a,8,12b-tetrahidro-2h-dibenzo [3,4:6,7]ciclohepta[1,2-b] furano transfundidos
BR0214775A (pt) Preparação de derivados de 3,3a,8,12b-tetraidro-2h-dibenzo[3,4:6,7]ciclohepta[1,2- b]furano cis-fundidos
MX386897B (es) Procedimiento simplificado para la preparacion de darunavir
MX172368B (es) Procedimiento para la fabricacion de un amortiguador de oscilacion rotatorio
CY1115086T1 (el) Αναλογα καρβα-νουκλεοζιτων για αντιϊικη αγωγη

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: TIBOTEC PHARMACEUTICALS LTD. (IE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070001806/RJ DE 05/01/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 493/04, A61P 31/00

Ipc: C07D 493/04 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/05/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.003778/2023-46 ORIGEM: 7A VARA FEDERAL CIVEL DA SJDF PROCESSO NO: 1014637-50.2023.4.01.3400 ACAO PELO PROCEDIMENTO COMUM COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: JANSSEN SCIENCES IRELAND UC REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.003778/2023-46 SECAO JUDICIARIA DO DISTRITO FEDERAL PROCESSO JUDICIAL: 1014637-50.2023.4.01.3400 AUTOR: JANSSEN SCIENCES IRELAND UC REUS: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI E OUTROS SENTENCA: PUBLICAR QUE O PRAZO DE VIGENCIA DA PATENTE OBJETO DESTA ACAO - PI0311176- 8 - ESTA SUB JUDICE, TANTO NA REVISTA DE PROPRIEDADE INDUSTRIAL, QUANTO NO STATUS DA RESPECTIVA PATENTE NO SITIO DO INPI NA INTERNET (ART. 59, INCISO II, 60 E 226 DA LPI.